<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing with OASIS Tables v3.0 20080202//EN" "journalpub-oasis3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xml:lang="en" dtd-version="3.0" article-type="research-article"><?xmltex \bartext{Original full-length article}?>
  <front>
    <journal-meta><journal-id journal-id-type="publisher">JBJI</journal-id><journal-title-group>
    <journal-title>Journal of Bone and Joint Infection</journal-title>
    <abbrev-journal-title abbrev-type="publisher">JBJI</abbrev-journal-title><abbrev-journal-title abbrev-type="nlm-ta">J. Bone Joint Infect.</abbrev-journal-title>
  </journal-title-group><issn pub-type="epub">2206-3552</issn><publisher>
    <publisher-name>Copernicus Publications</publisher-name>
    <publisher-loc>Göttingen, Germany</publisher-loc>
  </publisher></journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.5194/jbji-7-203-2022</article-id><title-group><article-title>Characteristics and outcomes of culture-negative prosthetic joint infections
from the Prosthetic Joint Infection in Australia and New Zealand
<?xmltex \hack{\break}?> Observational (PIANO) cohort study</article-title><alt-title>Culture-negative prosthetic joint infections</alt-title>
      </title-group><?xmltex \runningtitle{Culture-negative prosthetic joint infections}?><?xmltex \runningauthor{S. Browning et al.}?>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" rid="aff1 aff2">
          <name><surname>Browning</surname><given-names>Sarah</given-names></name>
          <email>sarah.browning@health.nsw.gov.au</email>
        </contrib>
        <contrib contrib-type="author" corresp="no" rid="aff3 aff4">
          <name><surname>Manning</surname><given-names>Laurens</given-names></name>
          
        </contrib>
        <contrib contrib-type="author" corresp="no" rid="aff5">
          <name><surname>Metcalf</surname><given-names>Sarah</given-names></name>
          
        </contrib>
        <contrib contrib-type="author" corresp="no" rid="aff6">
          <name><surname>Paterson</surname><given-names>David L.</given-names></name>
          
        </contrib>
        <contrib contrib-type="author" corresp="no" rid="aff7 aff8 aff9">
          <name><surname>Robinson</surname><given-names>James O.</given-names></name>
          
        <ext-link>https://orcid.org/0000-0002-7563-6180</ext-link></contrib>
        <contrib contrib-type="author" corresp="no" rid="aff3">
          <name><surname>Clark</surname><given-names>Benjamin</given-names></name>
          
        </contrib>
        <contrib contrib-type="author" corresp="no" rid="aff1 aff2 aff10">
          <name><surname>Davis</surname><given-names>Joshua S.</given-names></name>
          
        </contrib>
        <aff id="aff1"><label>1</label><institution>Infection Research Program, Hunter Medical Research Institute, Newcastle,
Australia</institution>
        </aff>
        <aff id="aff2"><label>2</label><institution>School of Medicine and Public Health, University of Newcastle, Newcastle,
Australia</institution>
        </aff>
        <aff id="aff3"><label>3</label><institution>Department of Infectious Diseases, Fiona Stanley Hospital, Perth, Australia</institution>
        </aff>
        <aff id="aff4"><label>4</label><institution>Medical School, The University of Western Australia, Perth, Australia</institution>
        </aff>
        <aff id="aff5"><label>5</label><institution>Department of Infectious Diseases, Christchurch Hospital, Christchurch, New
Zealand</institution>
        </aff>
        <aff id="aff6"><label>6</label><institution>UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland,  Brisbane, Australia</institution>
        </aff>
        <aff id="aff7"><label>7</label><institution>Department of Infectious Diseases, Royal Perth Hospital, Perth, Australia</institution>
        </aff>
        <aff id="aff8"><label>8</label><institution>PathWest Laboratory Medicine WA, Perth, Australia</institution>
        </aff>
        <aff id="aff9"><label>9</label><institution>College of Science, Health, Engineering and Education, Discipline of Health,<?xmltex \hack{\break}?>
Murdoch University, Perth, Australia</institution>
        </aff>
        <aff id="aff10"><label>10</label><institution>Global and Tropical Health Division, Menzies School of Health Research, <?xmltex \hack{\break}?>Charles Darwin University, Darwin, Australia</institution>
        </aff>
      </contrib-group>
      <author-notes><corresp id="corr1">Sarah Browning  (sarah.browning@health.nsw.gov.au)</corresp></author-notes><pub-date><day>20</day><month>September</month><year>2022</year></pub-date>
      
      <volume>7</volume>
      <issue>5</issue>
      <fpage>203</fpage><lpage>211</lpage>
      <history>
        <date date-type="received"><day>28</day><month>May</month><year>2022</year></date>
           <date date-type="rev-recd"><day>22</day><month>August</month><year>2022</year></date>
           <date date-type="accepted"><day>31</day><month>August</month><year>2022</year></date>
      </history>
      <permissions>
        <copyright-statement>Copyright: © 2022 Sarah Browning et al.</copyright-statement>
        <copyright-year>2022</copyright-year>
      <license license-type="open-access"><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><self-uri xlink:href="https://jbji.copernicus.org/articles/7/203/2022/jbji-7-203-2022.html">This article is available from https://jbji.copernicus.org/articles/7/203/2022/jbji-7-203-2022.html</self-uri><self-uri xlink:href="https://jbji.copernicus.org/articles/7/203/2022/jbji-7-203-2022.pdf">The full text article is available as a PDF file from https://jbji.copernicus.org/articles/7/203/2022/jbji-7-203-2022.pdf</self-uri>
      <abstract><title>Abstract</title>

      <p id="d1e203"><bold>Introduction</bold>:
Culture-negative (CN) prosthetic joint infections (PJIs) account for
approximately 10 % of all PJIs and present significant challenges for
clinicians. We aimed to explore the significance of CN PJIs within a large
prospective cohort study, comparing their characteristics and outcomes with
culture-positive (CP) cases.
<bold>Methods</bold>:
The Prosthetic joint Infection in Australia and New Zealand Observational
(PIANO) study is a prospective, multicentre observational cohort study
that was conducted at 27 hospitals between 2014 and 2017. We compared baseline
characteristics and outcomes of all patients with CN PJI from the PIANO
cohort with those of CP cases. We report on PJI diagnostic criteria in the CN cohort
and apply internationally recognized PJI diagnostic guidelines to determine
optimal CN PJI detection methods.
<bold>Results</bold>:
Of the 650 patients with 24-month outcome data  available, 55 (8.5 %) were
CN and 595 were CP. Compared with the CP cohort, CN patients were more
likely to be female (32 (58.2 %) vs. 245 (41.2 %); <inline-formula><mml:math id="M1" display="inline"><mml:mi>p</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M2" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 0.016), involve
the shoulder joint (5 (9.1 %) vs. 16 (2.7 %); <inline-formula><mml:math id="M3" display="inline"><mml:mi>p</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M4" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 0.026), and have a
lower mean C-reactive protein (142 mg L<inline-formula><mml:math id="M5" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> vs. 187 mg L<inline-formula><mml:math id="M6" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>; <inline-formula><mml:math id="M7" display="inline"><mml:mi>p</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M8" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 0.016). Overall,
outcomes were superior in CN patients, with culture negativity an
independent predictor of treatment success at 24 months (adjusted odds ratio, aOR, of 3.78 and 95 %CI of
1.65–8.67). Suboptimal diagnostic sampling was common in both cohorts,
with CN PJI case detection enhanced using the Infectious Diseases Society of
America PJI diagnostic guidelines.
<bold>Conclusions</bold>:
Current PJI diagnostic guidelines vary substantially in their ability to
detect CN PJI, with comprehensive diagnostic sampling necessary to achieve
diagnostic certainty. Definitive surgical management strategies should be
determined by careful assessment of infection type, rather than by culture
status alone.</p>
  </abstract>
    </article-meta>
  </front>
<body>
      

<sec id="Ch1.S1" sec-type="intro">
  <label>1</label><title>Introduction</title>
      <p id="d1e293">Prosthetic joint infection (PJI) is a devastating complication of joint
arthroplasty that is associated with significant patient morbidity and economic
burden (Del Pozo and Patel, 2009; Moore et al., 2015). PJI complicates
1 %–2 % of primary arthroplasties  (Del Pozo and Patel, 2009) and up to
8 % of cases following revision arthroplasty  (Quinlan et al., 2020).
Identification of pathogenic organisms from culture of synovial fluid and
periprosthetic tissue is a cornerstone of PJI diagnosis and treatment
decisions  (Parvizi et al., 2018; McNally et al., 2021; Osmon et al.,
2013). In approximately 10 % of all PJIs the diagnostic criteria
indicating a PJI are met, but no causative pathogen is isolated
(Reisener and Perka, 2018). In these situations, it is unclear if culture-negative (CN) PJI represents poor specificity of diagnostic criteria (i.e.
not an infection), an infection caused by a fastidious non-culturable
organism, or the absence of microbial growth as a consequence of antibiotic
exposure prior to sampling. While previous retrospective analyses have been
conducted, inconsistencies in inclusion criteria, classification of
infection type, and treatment success measures limit the opportunity for
direct comparisons and use in guiding clinical practice  (Reisener and
Perka, 2018; Peel et al., 2013).</p>
      <p id="d1e296">We aimed to explore the significance of CN PJI within a large prospective
cohort study and to compare their characteristics and outcomes with culture-positive (CP) cases.</p>
</sec>
<sec id="Ch1.S2">
  <label>2</label><title>Methods</title>
<sec id="Ch1.S2.SS1">
  <label>2.1</label><title>Participants and setting</title>
      <p id="d1e314">The Prosthetic joint Infection in Australia and New Zealand
Observational (PIANO) study was a prospective, binational, multicentre
observational cohort study that recruited at 27 hospitals between July 2014 and
December 2017. A total of 783 patients with confirmed PJI were enrolled,
comprising predominately knee (<inline-formula><mml:math id="M9" display="inline"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn mathvariant="normal">427</mml:mn></mml:mrow></mml:math></inline-formula>), hip (<inline-formula><mml:math id="M10" display="inline"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn mathvariant="normal">323</mml:mn></mml:mrow></mml:math></inline-formula>), and shoulder (<inline-formula><mml:math id="M11" display="inline"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn mathvariant="normal">25</mml:mn></mml:mrow></mml:math></inline-formula>)
joints. Detailed study methodology and baseline cohort characteristics
(Manning et al., 2020) as well as outcomes after 24-months of follow-up
have been described previously  (Davis et al., 2022) and are summarized
below.</p>
      <p id="d1e353">Adult patients (<inline-formula><mml:math id="M12" display="inline"><mml:mo lspace="0mm">&gt;</mml:mo></mml:math></inline-formula> 18 years) with a newly diagnosed PJI were
identified and enrolled following referral from an infectious diseases,
microbiology, or orthopaedic team member. PJI was defined, using the modified
Infectious Diseases Society of America (IDSA) PJI diagnostic guidelines,
(Zimmerli, 2014) as the clinical suspicion of PJI in the presence
of ongoing symptoms, including at least one of the following: (i) the presence of a
sinus tract communicating with the prosthesis; (ii) increased leukocyte count
or neutrophil percentage in preoperative synovial fluid aspirate (synovial
fluid white blood cell count <inline-formula><mml:math id="M13" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 1700 cells <inline-formula><mml:math id="M14" display="inline"><mml:mrow class="unit"><mml:mi mathvariant="normal">µ</mml:mi></mml:mrow></mml:math></inline-formula>L<inline-formula><mml:math id="M15" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> or neutrophil
percentage <inline-formula><mml:math id="M16" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 65 %); (iii) visible pus around the prosthesis
without an alternative explanation; (iv) acute inflammation reported on
postoperative examination of periprosthetic tissue (<inline-formula><mml:math id="M17" display="inline"><mml:mo lspace="0mm">≥</mml:mo></mml:math></inline-formula> 5 neutrophils per
high-power field); (v) <inline-formula><mml:math id="M18" display="inline"><mml:mo>≥</mml:mo></mml:math></inline-formula> 2 preoperative or intraoperative cultures
(blood, synovial fluid, periprosthetic tissue, or sonication fluid) that
yielded the same organism (indistinguishable based on common laboratory
tests); or (vi) pure growth of <italic>Staphylococcus aureus</italic>, <inline-formula><mml:math id="M19" display="inline"><mml:mi mathvariant="italic">β</mml:mi></mml:math></inline-formula>-hemolytic streptococci, or
pathogenic aerobic gram-negative rod from a single synovial fluid or
intraoperative tissue/fluid specimen. Standard culture-based methods were
used by all participating laboratories in processing blood cultures,
synovial fluid, and periprosthetic tissue. The number and type of diagnostic
samples were determined by local hospital policy and treating clinicians.</p>
</sec>
<sec id="Ch1.S2.SS2">
  <label>2.2</label><title>Definitions</title>
      <p id="d1e430">Infections were classified according to the duration of symptoms and time from
arthroplasty implantation, with the majority of patients classified as
either “early postoperative” (diagnosis occurring <inline-formula><mml:math id="M20" display="inline"><mml:mo>≤</mml:mo></mml:math></inline-formula> 30 d after the
original arthroplasty operation), “late acute” (diagnosis and onset of
symptoms occurring <inline-formula><mml:math id="M21" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 30 d from implantation but with a total
symptom duration of <inline-formula><mml:math id="M22" display="inline"><mml:mo>≤</mml:mo></mml:math></inline-formula> 7 d and no evidence of a sinus overlying the
joint), or “chronic” (<inline-formula><mml:math id="M23" display="inline"><mml:mo lspace="0mm">&gt;</mml:mo></mml:math></inline-formula> 30 d from implantation and symptoms
duration <inline-formula><mml:math id="M24" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 30 d at the time of diagnosis, or the presence of a
sinus). Those with late-onset PJI, a duration of symptoms between 8 and
30 d, and without the presence of a sinus were considered to have late
indeterminate infections, whereas the remainder were considered
unclassifiable. CN PJIs were defined as those having met study inclusion
criteria but with failure to isolate a causative pathogen from culture of
synovial fluid or periprosthetic tissue specimens obtained at the time of,
or prior to, the initial surgical intervention for suspected infection.</p>
</sec>
<sec id="Ch1.S2.SS3">
  <label>2.3</label><title>Data collection</title>
      <p id="d1e476">Data were collected and recorded prospectively in a purpose-built web-based
database at baseline, 3, 12, and 24 months post PJI diagnosis.
The primary outcome measure was treatment success at 24 months follow-up,
defined as being alive with no clinical or microbiological evidence of
infection, no longer taking antibiotics for suppression or treatment of the
PJI, and having the “key prosthesis” still in place. The key
prosthesis was defined as follows: (i) the index prosthesis present at
diagnosis for those whose main treatment strategy at day 90 was debridement and implant
retention (DAIR); (ii) the destination prosthesis for those whose main treatment strategy at day 90
was two-stage revision, even if the second stage was completed after day 90;
(iii) the destination prosthesis for those whose main treatment strategy at
day 90 was single-stage revision; and (iv) the index prosthesis for those who
managed with suppressive antibiotics with non-curative intent. All
participants provided written informed consent. We performed a post hoc
retrospective analysis of this prospectively collected data. Treatment was
not dictated by authors but was purely observational in design.</p>
</sec>
<sec id="Ch1.S2.SS4">
  <label>2.4</label><title>Inclusion criteria </title>
      <p id="d1e487">Of 783 patients enrolled, 653 had 24-month outcome data available and were
screened for eligibility for inclusion in the analysis. Following detailed
review, it was unclear in three cases whether modified IDSA PJI diagnostic
criteria were met. These patients were subsequently excluded, with 650
patients remaining in the analysis.</p>
      <p id="d1e490">Baseline demographic and clinical features were compared between CN and CP
cohorts. A comparison of treatment success at 24 months post PJI diagnosis
was performed and presented for the overall cohort as well as for infection
type and 90 d surgical management strategy.</p>
</sec>
<sec id="Ch1.S2.SS5">
  <label>2.5</label><title>PJI diagnostic guidelines</title>
      <p id="d1e502">In addition to the previously assessed modified IDSA diagnostic criteria, we
applied the following diagnostic criteria to all CN cases: (i) 2013
International Consensus Meeting (ICM) (Parvizi et al., 2013); (ii) 2018
ICM  (Parvizi et al., 2018), and (iii) 2021 European Bone and Joint
Infection Society (EBJIS)  (McNally et al., 2021). An erythrocyte
sedimentation rate (ESR) was not available; hence, an elevated C-reactive
protein (CRP) (<inline-formula><mml:math id="M25" display="inline"><mml:mo lspace="0mm">&gt;</mml:mo></mml:math></inline-formula> 10 mg L<inline-formula><mml:math id="M26" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>) was judged as having met the 2013 ICM
diagnostic criteria for elevated inflammatory markers in this cohort.</p>
</sec>
<sec id="Ch1.S2.SS6">
  <label>2.6</label><title>Statistical analysis</title>
      <p id="d1e532">Statistical analyses were conducted using IBM SPSS Statistics (version 26.0
Chicago, Illinois). Data were summarized using the mean (standard deviation) or
median (interquartile range) for normally and non-normally distributed
variables respectively. Categorical variables were compared using
chi-squared tests or Fisher's exact tests as appropriate. Means of
continuous variables were compared using an independent-samples <inline-formula><mml:math id="M27" display="inline"><mml:mi>t</mml:mi></mml:math></inline-formula> test where
data were normally distributed, and medians were compared using a Mann–Whitney <inline-formula><mml:math id="M28" display="inline"><mml:mi>U</mml:mi></mml:math></inline-formula>
test for nonparametric variables. Multivariate logistic regression using
backward stepwise selection was used to determine independent predictors of
success, with the 95 % confidence intervals presented. Two-tailed <inline-formula><mml:math id="M29" display="inline"><mml:mi>P</mml:mi></mml:math></inline-formula> values of
<inline-formula><mml:math id="M30" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula> 0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec id="Ch1.S3">
  <label>3</label><title>Results</title>
<sec id="Ch1.S3.SS1">
  <label>3.1</label><title>Demographics</title>
      <p id="d1e579">Of the 650 patients eligible for inclusion in this subgroup analysis, 55
(8.5 %) were classified as CN. The baseline characteristics of the CN
patients did not differ from those of the CP patients (Table 1), apart from
sex (CN more likely to be female), joint affected (CN more likely to be
shoulder joint than CP), and mean baseline C-reactive protein (lower in CN
cases).</p>

<?xmltex \floatpos{p}?><table-wrap id="Ch1.T1" specific-use="star"><?xmltex \currentcnt{1}?><label>Table 1</label><caption><p id="d1e585">Baseline characteristics of CN patients compared with CP
patients. </p></caption><oasis:table frame="topbot"><?xmltex \begin{scaleboxenv}{.95}[.95]?><oasis:tgroup cols="4">
     <oasis:colspec colnum="1" colname="col1" align="left"/>
     <oasis:colspec colnum="2" colname="col2" align="right"/>
     <oasis:colspec colnum="3" colname="col3" align="right"/>
     <oasis:colspec colnum="4" colname="col4" align="right"/>
     <oasis:thead>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Patient demographics</oasis:entry>
         <oasis:entry colname="col2">CN (<inline-formula><mml:math id="M31" display="inline"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn mathvariant="normal">55</mml:mn></mml:mrow></mml:math></inline-formula>)</oasis:entry>
         <oasis:entry colname="col3">CP (<inline-formula><mml:math id="M32" display="inline"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn mathvariant="normal">595</mml:mn></mml:mrow></mml:math></inline-formula>)</oasis:entry>
         <oasis:entry colname="col4"><inline-formula><mml:math id="M33" display="inline"><mml:mi>P</mml:mi></mml:math></inline-formula> value</oasis:entry>
       </oasis:row>
     </oasis:thead>
     <oasis:tbody>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Age</oasis:entry>
         <oasis:entry colname="col2">70.5 (15.8)</oasis:entry>
         <oasis:entry colname="col3">69.7 (15.3)</oasis:entry>
         <oasis:entry colname="col4">0.252</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Gender</oasis:entry>
         <oasis:entry colname="col2"/>
         <oasis:entry colname="col3"/>
         <oasis:entry colname="col4"/>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Male</oasis:entry>
         <oasis:entry colname="col2">23 (41.8)</oasis:entry>
         <oasis:entry colname="col3">350 (58.8)</oasis:entry>
         <oasis:entry colname="col4">0.016</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">BMI</oasis:entry>
         <oasis:entry colname="col2">31 (10.7)</oasis:entry>
         <oasis:entry colname="col3">31 (9.9)</oasis:entry>
         <oasis:entry colname="col4">0.158</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Comorbidities</oasis:entry>
         <oasis:entry colname="col2"/>
         <oasis:entry colname="col3"/>
         <oasis:entry colname="col4"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Diabetes</oasis:entry>
         <oasis:entry colname="col2">17 (30.9)</oasis:entry>
         <oasis:entry colname="col3">126 (21.3)</oasis:entry>
         <oasis:entry colname="col4">0.1</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Rheumatoid arthritis</oasis:entry>
         <oasis:entry colname="col2">7 (12.7)</oasis:entry>
         <oasis:entry colname="col3">41 (6.9)</oasis:entry>
         <oasis:entry colname="col4">0.171</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Chronic renal impairment</oasis:entry>
         <oasis:entry colname="col2">5 (9.1)</oasis:entry>
         <oasis:entry colname="col3">50 (8.4)</oasis:entry>
         <oasis:entry colname="col4">0.802</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">ESRF</oasis:entry>
         <oasis:entry colname="col2">0</oasis:entry>
         <oasis:entry colname="col3">5 (0.8)</oasis:entry>
         <oasis:entry colname="col4">1.0</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Cirrhosis</oasis:entry>
         <oasis:entry colname="col2">2 (3.6)</oasis:entry>
         <oasis:entry colname="col3">5 (0.8)</oasis:entry>
         <oasis:entry colname="col4">0.113</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Malignancy</oasis:entry>
         <oasis:entry colname="col2">3 (5.5)</oasis:entry>
         <oasis:entry colname="col3">24 (4.1)</oasis:entry>
         <oasis:entry colname="col4">0.494</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Congestive cardiac failure</oasis:entry>
         <oasis:entry colname="col2">2 (3.6)</oasis:entry>
         <oasis:entry colname="col3">33 (5.6)</oasis:entry>
         <oasis:entry colname="col4">0.759</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Ischemic heart disease</oasis:entry>
         <oasis:entry colname="col2">12 (21.8)</oasis:entry>
         <oasis:entry colname="col3">95 (16)</oasis:entry>
         <oasis:entry colname="col4">0.270</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Corticosteroid use</oasis:entry>
         <oasis:entry colname="col2">2 (3.6)</oasis:entry>
         <oasis:entry colname="col3">56 (9.5)</oasis:entry>
         <oasis:entry colname="col4">0.215</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Immunosuppressed</oasis:entry>
         <oasis:entry colname="col2">4 (7.3)</oasis:entry>
         <oasis:entry colname="col3">35 (5.9)</oasis:entry>
         <oasis:entry colname="col4">0.563</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Active orders limiting life-sustaining treatment</oasis:entry>
         <oasis:entry colname="col2">1 (1.8)</oasis:entry>
         <oasis:entry colname="col3">6 (1.0)</oasis:entry>
         <oasis:entry colname="col4">0.465</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Joint affected</oasis:entry>
         <oasis:entry colname="col2"/>
         <oasis:entry colname="col3"/>
         <oasis:entry colname="col4"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Knee</oasis:entry>
         <oasis:entry colname="col2">31 (56.4)</oasis:entry>
         <oasis:entry colname="col3">324 (54.5)</oasis:entry>
         <oasis:entry colname="col4">0.785</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Hip</oasis:entry>
         <oasis:entry colname="col2">18 (32.7)</oasis:entry>
         <oasis:entry colname="col3">249 (41.8)</oasis:entry>
         <oasis:entry colname="col4">0.188</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Shoulder</oasis:entry>
         <oasis:entry colname="col2">5 (9.1)</oasis:entry>
         <oasis:entry colname="col3">16 (2.7)</oasis:entry>
         <oasis:entry colname="col4">0.026</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Elbow</oasis:entry>
         <oasis:entry colname="col2">1 (1.8)</oasis:entry>
         <oasis:entry colname="col3">4 (0.7)</oasis:entry>
         <oasis:entry colname="col4">0.358</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Ankle</oasis:entry>
         <oasis:entry colname="col2">0</oasis:entry>
         <oasis:entry colname="col3">2 (0.3)</oasis:entry>
         <oasis:entry colname="col4">1.0</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Side</oasis:entry>
         <oasis:entry colname="col2"/>
         <oasis:entry colname="col3"/>
         <oasis:entry colname="col4"/>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Right</oasis:entry>
         <oasis:entry colname="col2">30 (54.5)</oasis:entry>
         <oasis:entry colname="col3">337 (56.6)</oasis:entry>
         <oasis:entry colname="col4">0.765</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Timing</oasis:entry>
         <oasis:entry colname="col2"/>
         <oasis:entry colname="col3"/>
         <oasis:entry colname="col4"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Time from implant to symptoms (d)</oasis:entry>
         <oasis:entry colname="col2">286 (1491)</oasis:entry>
         <oasis:entry colname="col3">249 (1381)</oasis:entry>
         <oasis:entry colname="col4">0.798</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Time from implant to diagnosis (d)</oasis:entry>
         <oasis:entry colname="col2">666 (2312)</oasis:entry>
         <oasis:entry colname="col3">332 (1497)</oasis:entry>
         <oasis:entry colname="col4">0.634</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Time from symptoms to diagnosis (d)</oasis:entry>
         <oasis:entry colname="col2">3 (12)</oasis:entry>
         <oasis:entry colname="col3">4 (12)</oasis:entry>
         <oasis:entry colname="col4">0.56</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Indication for original implant</oasis:entry>
         <oasis:entry colname="col2"/>
         <oasis:entry colname="col3"/>
         <oasis:entry colname="col4"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Primary</oasis:entry>
         <oasis:entry colname="col2">45 (81.8)</oasis:entry>
         <oasis:entry colname="col3">478 (80.3)</oasis:entry>
         <oasis:entry colname="col4">0.791</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Infection</oasis:entry>
         <oasis:entry colname="col2">0</oasis:entry>
         <oasis:entry colname="col3">29 (4.9)</oasis:entry>
         <oasis:entry colname="col4">0.162</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Other/unknown</oasis:entry>
         <oasis:entry colname="col2">10 (18.2)</oasis:entry>
         <oasis:entry colname="col3">75 (12.6)</oasis:entry>
         <oasis:entry colname="col4">0.241</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Clinical features at time of presentation</oasis:entry>
         <oasis:entry colname="col2"/>
         <oasis:entry colname="col3"/>
         <oasis:entry colname="col4"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Fever: temperature <inline-formula><mml:math id="M34" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 38<inline-formula><mml:math id="M35" display="inline"><mml:msup><mml:mi/><mml:mo>∘</mml:mo></mml:msup></mml:math></inline-formula> on at least one occasion <inline-formula><mml:math id="M36" display="inline"><mml:mo>±</mml:mo></mml:math></inline-formula>48 h</oasis:entry>
         <oasis:entry colname="col2">21 (38.2)</oasis:entry>
         <oasis:entry colname="col3">236 (39.7)</oasis:entry>
         <oasis:entry colname="col4">0.83</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Local inflammation: redness or warmth around the index joint</oasis:entry>
         <oasis:entry colname="col2">48 (87.3)</oasis:entry>
         <oasis:entry colname="col3">471 (79.2)</oasis:entry>
         <oasis:entry colname="col4">0.151</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Sepsis: systolic BP <inline-formula><mml:math id="M37" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula> 90 mmHg despite adequate IV fluids <italic>or</italic> the need for vasopressors/inotropes</oasis:entry>
         <oasis:entry colname="col2">2 (3.6)</oasis:entry>
         <oasis:entry colname="col3">26 (4.4)</oasis:entry>
         <oasis:entry colname="col4">1.0</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Laboratory findings</oasis:entry>
         <oasis:entry colname="col2"/>
         <oasis:entry colname="col3"/>
         <oasis:entry colname="col4"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Leukocyte count (<inline-formula><mml:math id="M38" display="inline"><mml:mo lspace="0mm">×</mml:mo></mml:math></inline-formula> 109 L<inline-formula><mml:math id="M39" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>)</oasis:entry>
         <oasis:entry colname="col2">11 (6.3)</oasis:entry>
         <oasis:entry colname="col3">11.2 (6.7)</oasis:entry>
         <oasis:entry colname="col4">0.921</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Neutrophil count (<inline-formula><mml:math id="M40" display="inline"><mml:mo lspace="0mm">×</mml:mo></mml:math></inline-formula> 109 L<inline-formula><mml:math id="M41" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>)</oasis:entry>
         <oasis:entry colname="col2">8.4 (6.3)</oasis:entry>
         <oasis:entry colname="col3">8.5 (6.2)</oasis:entry>
         <oasis:entry colname="col4">6.33</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">C-reactive protein (mg L<inline-formula><mml:math id="M42" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>)</oasis:entry>
         <oasis:entry colname="col2">116 (126)</oasis:entry>
         <oasis:entry colname="col3">175.5 (208)</oasis:entry>
         <oasis:entry colname="col4">0.01</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Creatinine (<inline-formula><mml:math id="M43" display="inline"><mml:mrow class="unit"><mml:mi mathvariant="normal">µ</mml:mi><mml:mi mathvariant="normal">mol</mml:mi></mml:mrow></mml:math></inline-formula> L<inline-formula><mml:math id="M44" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>)</oasis:entry>
         <oasis:entry colname="col2">83 (33)</oasis:entry>
         <oasis:entry colname="col3">85 (46)</oasis:entry>
         <oasis:entry colname="col4">0.875</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Albumin (g L<inline-formula><mml:math id="M45" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, mean (SD))</oasis:entry>
         <oasis:entry colname="col2">31 (6)</oasis:entry>
         <oasis:entry colname="col3">31 (7)</oasis:entry>
         <oasis:entry colname="col4">0.503</oasis:entry>
       </oasis:row>
     </oasis:tbody>
   </oasis:tgroup><?xmltex \end{scaleboxenv}?></oasis:table><?xmltex \begin{scaleboxenv}{.95}[.95]?><table-wrap-foot><p id="d1e588">
The abbreviations used in the table are as follows: d – days, IV – intravenous, BMI – body mass index, ESRF – end-stage renal failure, and DAIR – debridement and implant retention.
Data are no. (%) for categorical variables and median (interquartile
range) for continuous variables, unless otherwise stated.</p></table-wrap-foot><?xmltex \end{scaleboxenv}?></table-wrap>

      <p id="d1e1386">Late acute PJI was the most common CN infection type, present in 21 of 55
(38.2 %) cases. A total of 16 of 55 cases (29.1 %) were early postoperative, 12 of 55 cases
(21.8 %) were chronic, and 6 of 55 cases (10.9 %) were not classifiable (1 late
indeterminate and 5 late unclassifiable). No differences in infection type
were observed between CN and CP groups. Two patients (3.6 %) died within the
24-month follow-up period.</p>
      <p id="d1e1390">No significant differences in diagnostic sampling were observed between CN
and CP (Table 2). It is of note that only one laboratory routinely performed sonication, while 16S polymerase chain reaction (PCR) was not routinely
performed or requested by any laboratory.</p>

<?xmltex \floatpos{t}?><table-wrap id="Ch1.T2" specific-use="star"><?xmltex \currentcnt{2}?><label>Table 2</label><caption><p id="d1e1396">Prosthetic joint infection diagnostic criteria.</p></caption><oasis:table frame="topbot"><oasis:tgroup cols="4">
     <oasis:colspec colnum="1" colname="col1" align="left"/>
     <oasis:colspec colnum="2" colname="col2" align="right"/>
     <oasis:colspec colnum="3" colname="col3" align="right"/>
     <oasis:colspec colnum="4" colname="col4" align="right"/>
     <oasis:thead>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">PJI diagnostic criterion</oasis:entry>
         <oasis:entry colname="col2">Culture negative,  <inline-formula><mml:math id="M46" display="inline"><mml:mi>N</mml:mi></mml:math></inline-formula> (%)</oasis:entry>
         <oasis:entry colname="col3">Culture positive,  <inline-formula><mml:math id="M47" display="inline"><mml:mi>N</mml:mi></mml:math></inline-formula> (%)</oasis:entry>
         <oasis:entry colname="col4"><inline-formula><mml:math id="M48" display="inline"><mml:mi>P</mml:mi></mml:math></inline-formula> value</oasis:entry>
       </oasis:row>
     </oasis:thead>
     <oasis:tbody>
       <oasis:row>
         <oasis:entry colname="col1">Presence of a sinus tract</oasis:entry>
         <oasis:entry colname="col2">15 of 55 (27.3)</oasis:entry>
         <oasis:entry colname="col3">120 of 595 (20.2)</oasis:entry>
         <oasis:entry colname="col4">0.214</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Visible purulence at operation</oasis:entry>
         <oasis:entry colname="col2">31 of 55 (56.4)</oasis:entry>
         <oasis:entry colname="col3">269 of 595 (45.2)</oasis:entry>
         <oasis:entry colname="col4">0.112</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Preoperative closed-needle joint aspiration done</oasis:entry>
         <oasis:entry colname="col2">24 of 55 (43.6)</oasis:entry>
         <oasis:entry colname="col3">258 of 595 (43.4)</oasis:entry>
         <oasis:entry colname="col4">0.969</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Intra-operative synovial fluid collected</oasis:entry>
         <oasis:entry colname="col2">38 of 49 (77.6)</oasis:entry>
         <oasis:entry colname="col3">464 of 576 (80.6)</oasis:entry>
         <oasis:entry colname="col4">0.612</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Number of periprosthetic specimens sent for culture</oasis:entry>
         <oasis:entry colname="col2">4.1 (1.7)</oasis:entry>
         <oasis:entry colname="col3">4.0 (1.9)</oasis:entry>
         <oasis:entry colname="col4">0.757</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1"><inline-formula><mml:math id="M49" display="inline"><mml:mrow><mml:mo>≥</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:math></inline-formula> tissue sent for histopathology</oasis:entry>
         <oasis:entry colname="col2">17 of 45 (37.8)</oasis:entry>
         <oasis:entry colname="col3">154 of 526 (29.3)</oasis:entry>
         <oasis:entry colname="col4">0.232</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Number of periprosthetic specimens sent for histology</oasis:entry>
         <oasis:entry colname="col2">0.89 (1.8)</oasis:entry>
         <oasis:entry colname="col3">0.45 (1.0)</oasis:entry>
         <oasis:entry colname="col4">0.104</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Serum C-reactive protein <inline-formula><mml:math id="M50" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 10 mg L<inline-formula><mml:math id="M51" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></oasis:entry>
         <oasis:entry colname="col2">50 of 55 (98)</oasis:entry>
         <oasis:entry colname="col3">554 of 578 (96.4)</oasis:entry>
         <oasis:entry colname="col4">1.0</oasis:entry>
       </oasis:row>
     </oasis:tbody>
   </oasis:tgroup></oasis:table><table-wrap-foot><p id="d1e1399">The abbreviations used in the table are as follows: PJI – prosthetic joint infection, IV – intravenous fluids, WCC –
white cell count, and CRP – C-reactive protein.</p></table-wrap-foot></table-wrap>

</sec>
<sec id="Ch1.S3.SS2">
  <label>3.2</label><title>PJI diagnostic criteria</title>
      <p id="d1e1613">When compared to the 2014 modified IDSA criteria, the 2013 ICM (70.9 %),
2018 ICM (63.6 %), and 2021 EBJIS (definite and likely) (80 %) criteria
were less likely to diagnose PJI in this cohort (Table 3). Amongst the 10 CN
patients who failed to meet the 2021 EBJIS diagnostic criteria, suboptimal
diagnostic sampling and visible purulence around the prosthesis were found
to be uniformly present (see Table S1 in the Supplement). Following
detailed review, only 1 of these 10 cases (patient no. 6, Table S1) was
deemed unlikely to have a true PJI, having failed to demonstrate definitive
histopathological or microbiological evidence of infection despite an
extensive diagnostic workup having been performed.</p>

<?xmltex \floatpos{t}?><table-wrap id="Ch1.T3" specific-use="star"><?xmltex \currentcnt{3}?><label>Table 3</label><caption><p id="d1e1619">Comparison of modified IDSA, EBJIS, and ICM diagnostic
criteria with IDSA for CN PJI.</p></caption><oasis:table frame="topbot"><oasis:tgroup cols="2">
     <oasis:colspec colnum="1" colname="col1" align="left"/>
     <oasis:colspec colnum="2" colname="col2" align="right"/>
     <oasis:thead>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Diagnostic criteria</oasis:entry>
         <oasis:entry colname="col2">CN cases meeting PJI diagnostic criteria (<inline-formula><mml:math id="M52" display="inline"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn mathvariant="normal">55</mml:mn></mml:mrow></mml:math></inline-formula>)</oasis:entry>
       </oasis:row>
     </oasis:thead>
     <oasis:tbody>
       <oasis:row rowsep="1">
         <oasis:entry namest="col1" nameend="col2">2014 Modified Infectious Diseases Society of America criteria </oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Definite</oasis:entry>
         <oasis:entry colname="col2">55 (100)</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry namest="col1" nameend="col2">2013 International Consensus Meeting criteria </oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Definite</oasis:entry>
         <oasis:entry colname="col2">39 (70.9)</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry namest="col1" nameend="col2">2018 International Consensus Meeting criteria </oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Definite</oasis:entry>
         <oasis:entry colname="col2">35 (63.6)</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Inconclusive</oasis:entry>
         <oasis:entry colname="col2">14 (25.5)</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Not infected</oasis:entry>
         <oasis:entry colname="col2">5 (9.1)</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry namest="col1" nameend="col2">2018 European Bone and Joint Infection Society criteria </oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Definite</oasis:entry>
         <oasis:entry colname="col2">41 (83.6)</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Likely</oasis:entry>
         <oasis:entry colname="col2">4 (74.6)</oasis:entry>
       </oasis:row>
     </oasis:tbody>
   </oasis:tgroup></oasis:table><table-wrap-foot><p id="d1e1622">The abbreviations used in the table are as follows: CN – culture negative and PJI – prosthetic joint infection</p></table-wrap-foot></table-wrap>

</sec>
<sec id="Ch1.S3.SS3">
  <label>3.3</label><title>Surgical management and 24-month treatment success</title>
      <p id="d1e1757">Within the CN cohort, DAIR was the most common surgical treatment strategy
(30 of 55 cases, 54.6 %), followed by two-stage revision (13 of 55 cases, 23.6 %) (Table 4).</p>

<?xmltex \floatpos{t}?><table-wrap id="Ch1.T4" specific-use="star"><?xmltex \currentcnt{4}?><label>Table 4</label><caption><p id="d1e1763">Infection type, index surgery, and treatment success in
culture-negative and culture-positive prosthetic joint infections.</p></caption><oasis:table frame="topbot"><?xmltex \begin{scaleboxenv}{.9}[.9]?><oasis:tgroup cols="5">
     <oasis:colspec colnum="1" colname="col1" align="left"/>
     <oasis:colspec colnum="2" colname="col2" align="left"/>
     <oasis:colspec colnum="3" colname="col3" align="right"/>
     <oasis:colspec colnum="4" colname="col4" align="right"/>
     <oasis:colspec colnum="5" colname="col5" align="right"/>
     <oasis:thead>
       <oasis:row>
         <oasis:entry colname="col1"/>
         <oasis:entry colname="col2"/>
         <oasis:entry rowsep="1" namest="col3" nameend="col4" align="center">Treatment success at 24 months </oasis:entry>
         <oasis:entry colname="col5"/>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">Infection category</oasis:entry>
         <oasis:entry colname="col2">Main management strategy at day 90</oasis:entry>
         <oasis:entry colname="col3">Culture negative, <inline-formula><mml:math id="M53" display="inline"><mml:mi>N</mml:mi></mml:math></inline-formula> (%) <?xmltex \hack{\hfill\break}?></oasis:entry>
         <oasis:entry colname="col4">Culture positive, <inline-formula><mml:math id="M54" display="inline"><mml:mi>N</mml:mi></mml:math></inline-formula> (%)</oasis:entry>
         <oasis:entry colname="col5"><inline-formula><mml:math id="M55" display="inline"><mml:mi>P</mml:mi></mml:math></inline-formula> value</oasis:entry>
       </oasis:row>
     </oasis:thead>
     <oasis:tbody>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1">All infection types combined (<inline-formula><mml:math id="M56" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M57" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 650)</oasis:entry>
         <oasis:entry colname="col2">All combined</oasis:entry>
         <oasis:entry colname="col3">41 of 55 (74.5)</oasis:entry>
         <oasis:entry colname="col4">308 of 595 (51.8)</oasis:entry>
         <oasis:entry colname="col5">0.001</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Late acute (<inline-formula><mml:math id="M58" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M59" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 267)</oasis:entry>
         <oasis:entry colname="col2">All management types combined</oasis:entry>
         <oasis:entry colname="col3">15 of 21 (71.4)</oasis:entry>
         <oasis:entry colname="col4">117 of 246 (47.6)</oasis:entry>
         <oasis:entry colname="col5">0.036</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1"/>
         <oasis:entry colname="col2">DAIR (<inline-formula><mml:math id="M60" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M61" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 162)</oasis:entry>
         <oasis:entry colname="col3">13 of 16 (81.3)</oasis:entry>
         <oasis:entry colname="col4">66 of 147 (44.9)</oasis:entry>
         <oasis:entry colname="col5">0.006</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1"/>
         <oasis:entry colname="col2">Two-stage revision (<inline-formula><mml:math id="M62" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M63" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 57)</oasis:entry>
         <oasis:entry colname="col3">1 of 2 (50)</oasis:entry>
         <oasis:entry colname="col4">40 of 55 (72.7)</oasis:entry>
         <oasis:entry colname="col5">0.486</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Early (<inline-formula><mml:math id="M64" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M65" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 160)</oasis:entry>
         <oasis:entry colname="col2">All management types combined</oasis:entry>
         <oasis:entry colname="col3">14 of 16 (87.5)</oasis:entry>
         <oasis:entry colname="col4">105 of 144 (72.9)</oasis:entry>
         <oasis:entry colname="col5">0.364</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1"/>
         <oasis:entry colname="col2">DAIR (<inline-formula><mml:math id="M66" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M67" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 111)</oasis:entry>
         <oasis:entry colname="col3">10 of 11 (90.9)</oasis:entry>
         <oasis:entry colname="col4">78 of 100 (78)</oasis:entry>
         <oasis:entry colname="col5">0.454</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1"/>
         <oasis:entry colname="col2">Two-stage revision (<inline-formula><mml:math id="M68" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M69" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 29)</oasis:entry>
         <oasis:entry colname="col3">2 of 2 (100)</oasis:entry>
         <oasis:entry colname="col4">21 of 27 (77.8)</oasis:entry>
         <oasis:entry colname="col5">1.0</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Chronic (<inline-formula><mml:math id="M70" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M71" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 141)</oasis:entry>
         <oasis:entry colname="col2">All management types combined</oasis:entry>
         <oasis:entry colname="col3">6 of 12 (50)</oasis:entry>
         <oasis:entry colname="col4">57 of 129 (44.2)</oasis:entry>
         <oasis:entry colname="col5">0.698</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1"/>
         <oasis:entry colname="col2">DAIR (<inline-formula><mml:math id="M72" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M73" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 44)</oasis:entry>
         <oasis:entry colname="col3">0 of 2</oasis:entry>
         <oasis:entry colname="col4">15 of 42 (35.7)</oasis:entry>
         <oasis:entry colname="col5">0.540</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1"/>
         <oasis:entry colname="col2">Two-stage revision (<inline-formula><mml:math id="M74" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M75" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 61)</oasis:entry>
         <oasis:entry colname="col3">5 of 7 (71.4)</oasis:entry>
         <oasis:entry colname="col4">30 of 54 (55.6)</oasis:entry>
         <oasis:entry colname="col5">0.688</oasis:entry>
       </oasis:row>
     </oasis:tbody>
   </oasis:tgroup><?xmltex \end{scaleboxenv}?></oasis:table></table-wrap>

      <p id="d1e2154">Despite this, culture negativity was associated with an increased likelihood
of treatment success overall (41 of 55 cases, 74.5 %, vs. 308 of 595 cases, 51.8 %;
<inline-formula><mml:math id="M76" display="inline"><mml:mi>p</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M77" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 0.001), and it was an independent predictor of treatment success at 24 months (adjusted odds ratio, aOR, of 3.78 and 95 %CI of 1.65–8.67) (Table 5).</p>

<?xmltex \floatpos{t}?><table-wrap id="Ch1.T5" specific-use="star"><?xmltex \currentcnt{5}?><label>Table 5</label><caption><p id="d1e2175">Independent predictors of treatment success at 24 months
(<inline-formula><mml:math id="M78" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> <inline-formula><mml:math id="M79" display="inline"><mml:mo>=</mml:mo></mml:math></inline-formula> 650).</p></caption><oasis:table frame="topbot"><oasis:tgroup cols="6">
     <oasis:colspec colnum="1" colname="col1" align="left"/>
     <oasis:colspec colnum="2" colname="col2" align="right"/>
     <oasis:colspec colnum="3" colname="col3" align="right"/>
     <oasis:colspec colnum="4" colname="col4" align="right"/>
     <oasis:colspec colnum="5" colname="col5" align="right"/>
     <oasis:colspec colnum="6" colname="col6" align="right"/>
     <oasis:thead>
       <oasis:row>
         <oasis:entry colname="col1">Variable</oasis:entry>
         <oasis:entry colname="col2">OR Rx success</oasis:entry>
         <oasis:entry colname="col3">95 % CI</oasis:entry>
         <oasis:entry colname="col4">aOR</oasis:entry>
         <oasis:entry colname="col5">95 % CI</oasis:entry>
         <oasis:entry colname="col6"><inline-formula><mml:math id="M80" display="inline"><mml:mi>P</mml:mi></mml:math></inline-formula> value</oasis:entry>
       </oasis:row>
       <oasis:row rowsep="1">
         <oasis:entry colname="col1"/>
         <oasis:entry colname="col2">at 24 months</oasis:entry>
         <oasis:entry colname="col3"/>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
     </oasis:thead>
     <oasis:tbody>
       <oasis:row>
         <oasis:entry colname="col1">Age</oasis:entry>
         <oasis:entry colname="col2">0.97</oasis:entry>
         <oasis:entry colname="col3">0.96–0.99</oasis:entry>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Body mass index</oasis:entry>
         <oasis:entry colname="col2">1.02</oasis:entry>
         <oasis:entry colname="col3">1.0–1.05</oasis:entry>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Hip</oasis:entry>
         <oasis:entry colname="col2">1.58</oasis:entry>
         <oasis:entry colname="col3">1.15–2.16</oasis:entry>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Knee</oasis:entry>
         <oasis:entry colname="col2">0.6</oasis:entry>
         <oasis:entry colname="col3">0.44–0.81</oasis:entry>
         <oasis:entry colname="col4">0.57</oasis:entry>
         <oasis:entry colname="col5">0.38–0.87</oasis:entry>
         <oasis:entry colname="col6">0.009</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Shoulder</oasis:entry>
         <oasis:entry colname="col2">1.42</oasis:entry>
         <oasis:entry colname="col3">0.58–3.47</oasis:entry>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Symptom duration <inline-formula><mml:math id="M81" display="inline"><mml:mo>≤</mml:mo></mml:math></inline-formula> 7 d at diagnosis</oasis:entry>
         <oasis:entry colname="col2">1.59</oasis:entry>
         <oasis:entry colname="col3">1.14–2.22</oasis:entry>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Symptom duration <inline-formula><mml:math id="M82" display="inline"><mml:mo>≤</mml:mo></mml:math></inline-formula> 21 d at diagnosis</oasis:entry>
         <oasis:entry colname="col2">1.5</oasis:entry>
         <oasis:entry colname="col3">1.01–2.23</oasis:entry>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Early postoperative</oasis:entry>
         <oasis:entry colname="col2">3.29</oasis:entry>
         <oasis:entry colname="col3">2.21–4.89</oasis:entry>
         <oasis:entry colname="col4">3.04</oasis:entry>
         <oasis:entry colname="col5">1.83–5.05</oasis:entry>
         <oasis:entry colname="col6">0.002</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Late acute</oasis:entry>
         <oasis:entry colname="col2">0.75</oasis:entry>
         <oasis:entry colname="col3">0.55–1.02</oasis:entry>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Chronic</oasis:entry>
         <oasis:entry colname="col2">0.63</oasis:entry>
         <oasis:entry colname="col3">0.43–0.92</oasis:entry>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Baseline CRP <inline-formula><mml:math id="M83" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 10 mg L<inline-formula><mml:math id="M84" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></oasis:entry>
         <oasis:entry colname="col2">0.33</oasis:entry>
         <oasis:entry colname="col3">0.12–0.89</oasis:entry>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Baseline CRP <inline-formula><mml:math id="M85" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 100 mg L<inline-formula><mml:math id="M86" display="inline"><mml:msup><mml:mi/><mml:mrow><mml:mo>-</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></oasis:entry>
         <oasis:entry colname="col2">0.68</oasis:entry>
         <oasis:entry colname="col3">0.48–0.95</oasis:entry>
         <oasis:entry colname="col4"/>
         <oasis:entry colname="col5"/>
         <oasis:entry colname="col6"/>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Baseline albumin</oasis:entry>
         <oasis:entry colname="col2">1.05</oasis:entry>
         <oasis:entry colname="col3">1.03–1.08</oasis:entry>
         <oasis:entry colname="col4">1.05</oasis:entry>
         <oasis:entry colname="col5">1.02–1.08</oasis:entry>
         <oasis:entry colname="col6">0.001</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1"><inline-formula><mml:math id="M87" display="inline"><mml:mrow><mml:mo>≥</mml:mo><mml:mn mathvariant="normal">1</mml:mn></mml:mrow></mml:math></inline-formula> comorbidity</oasis:entry>
         <oasis:entry colname="col2">0.56</oasis:entry>
         <oasis:entry colname="col3">0.41–0.77</oasis:entry>
         <oasis:entry colname="col4">0.62</oasis:entry>
         <oasis:entry colname="col5">0.42–0.92</oasis:entry>
         <oasis:entry colname="col6">0.016</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Sinus present</oasis:entry>
         <oasis:entry colname="col2">0.65</oasis:entry>
         <oasis:entry colname="col3">0.44–0.95</oasis:entry>
         <oasis:entry colname="col4">0.58</oasis:entry>
         <oasis:entry colname="col5">0.35–0.95</oasis:entry>
         <oasis:entry colname="col6">0.032</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">DAIR at 90 d</oasis:entry>
         <oasis:entry colname="col2">1.22</oasis:entry>
         <oasis:entry colname="col3">0.9–1.66</oasis:entry>
         <oasis:entry colname="col4">2.41</oasis:entry>
         <oasis:entry colname="col5">1.39–4.18</oasis:entry>
         <oasis:entry colname="col6">0.002</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Two-stage revision at 90 d</oasis:entry>
         <oasis:entry colname="col2">1.89</oasis:entry>
         <oasis:entry colname="col3">1.31–2.72</oasis:entry>
         <oasis:entry colname="col4">5.47</oasis:entry>
         <oasis:entry colname="col5">2.94–10.15</oasis:entry>
         <oasis:entry colname="col6"><inline-formula><mml:math id="M88" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula> 0.001</oasis:entry>
       </oasis:row>
       <oasis:row>
         <oasis:entry colname="col1">Culture negative</oasis:entry>
         <oasis:entry colname="col2">2.81</oasis:entry>
         <oasis:entry colname="col3">1.5–5.24</oasis:entry>
         <oasis:entry colname="col4">3.78</oasis:entry>
         <oasis:entry colname="col5">1.65–8.67</oasis:entry>
         <oasis:entry colname="col6">0.002</oasis:entry>
       </oasis:row>
     </oasis:tbody>
   </oasis:tgroup></oasis:table><table-wrap-foot><p id="d1e2192">“OR Rx success” refers to the odds ratio of treatment success. </p></table-wrap-foot></table-wrap>

      <p id="d1e2698">By infection type, improved outcomes were demonstrated only in late acute CN
PJIs and was most pronounced in those managed with DAIR (13 of 17 cases, 81.3 %,
vs. 66 of 147 cases, 44.9 %; aOR of 5.3 and 95 %CI of 1.5–19.5) (Tables 4, S2).</p>
</sec>
</sec>
<sec id="Ch1.S4">
  <label>4</label><title>Discussion</title>
      <p id="d1e2710">This multicentre retrospective analysis offers important insights into the
presenting features, demographics, and expected treatment outcomes in CN PJI.
In contrast to previous reports  (Parikh and Antony, 2015), our findings
do not support the notion that atypical pathogens play a significant role in
CN PJI. Instead, striking similarities between CN and CP patients mean that
risk factors, such antibiotic exposure, suboptimal sampling practices, and
delays in laboratory processing, are more likely to be implicated
(Kang et al., 2018).</p>
      <p id="d1e2713">Of those eligible for study inclusion, 8.5 % were classified as being CN,
which is lower than the reported pooled incidence rate of 11 %
(Reisener and Perka, 2018). This may relate to differences in diagnostic
approaches or laboratory processing methods across geographical locations
and health networks. It is of note that sonication was only routinely used at one of
the participating laboratories.</p>
      <p id="d1e2716">Overall, baseline demographics were similar between the CN and CP cohorts.
However, it is interesting to note the higher proportion of shoulder
infections within the CN cohort, which is likely explained by difficulties
encountered in the isolation of <italic>Cutibacterium acnes</italic> using typical culture methods, with an
extended incubation time of up to 14 d sometimes required  (Foster et
al., 2021). While standard culture techniques were utilized by all
participating laboratories, the duration of extended culture was not
standardized and may have resulted in the reduced sensitivity of pathogen
detection. In contrast to previously studied CN cohorts  (Choi et al.,
2013; Kim et al., 2015), late acute PJI was found to be the predominant
infection type; while heterogenous infection type definitions may have
contributed to this (Tsukayama et al., 1996), crystal arthropathy as a mimicker
of bacterial PJI may provide an alternate explanation for this finding
(Khalfaoui and Yassa, 2015).</p>
      <p id="d1e2722">The EBJIS criteria were not met for 10 (18.2 %) of the CN cohort. This could
either mean that the 2021 EBJIS criteria are less sensitive than the 2014 modified
IDSA criteria or that they are more specific. As there is no gold standard test for PJI in the absence of
culture positivity, it is not
possible to definitively say which of these is the true explanation.</p>
      <p id="d1e2726">Both the number and type of periprosthetic specimens submitted for bacterial
culture are known to impact upon the sensitivity and specificity of pathogen
detection in PJIs (Peel et al., 2017). While the mean number of
specimens collected was less than guideline-based recommendations  (Osmon
et al., 2013; Peel et al., 2017), this did not appear to contribute to a
reduction in identifiable causative pathogens, with no significant
differences in diagnostic sampling observed between the two groups.
Suboptimal diagnostic sampling methods did appear to impact on PJI
diagnostic certainty, however, with a notable absence of histopathological
examination and synovial fluid analysis in the majority of the 10 cases
that failed to meet the 2021 EBJIS PJI criteria (Table S1). Instead, visible
purulence around the prosthesis was the sole definitive diagnostic criterion
present in all 10 cases. While the value of visible purulence has been
questioned due to its subjective nature and poor specificity
(Alijanipour et al., 2015), our findings highlight the potential value
of this diagnostic criterion when applied in a real-life setting, where
suboptimal diagnostic sampling is frequently encountered.</p>
      <p id="d1e2729">In accordance with existing literature about CN PJI  (Kang et al., 2018;
Choi et al., 2013; Paz et al., 2021), we demonstrate improved overall
outcomes when compared with CP cases, despite no observed difference in the
incidence of fever or sepsis between cohorts  (Paz et al., 2021).
When compared with CP patients, CN late acute infections managed with DAIR
were 5.3 times more likely to experience treatment success (95 %CI of
1.5–19.5). This finding has not been demonstrated in other CN cohorts
(Kim et al., 2015; Choi et al., 2013) but may be explained by the
factors outlined in the following. Firstly, pre-administration of antibiotics is a known
predictor of CN PJI  (Berbari et al., 2007; Malekzadeh et al., 2010);
hence, in late acute presentations, CN PJI may represent a cohort in which the
causative pathogen is more readily eradicated or suppressed. A lack of
biofilm formation and increased pathogen susceptibility does not provide a
complete explanation for these findings, however, given similar outcomes
observed in early postoperative CN and CP cohorts. Instead, this finding
further supports the concept that late acute PJI represents a heterogenous
cohort, where a subset of CN late acute infections may represent chronic
bacterial infections with short overt symptom durations  (Davis et al.,
2022). Additionally, crystal arthropathies due to monosodium urate and
calcium pyrophosphate dihydrate deposition do not form part of routine PJI
investigation and may account for a proportion of late acute presentations
and improved outcomes. While further inaccuracies in the diagnosis of CN PJI
could also explain these findings, detailed examination of the presenting
features and diagnostic criterion of this cohort (see Table S2) does not support this.</p>
      <p id="d1e2732">Our study does have some limitations. For example, antibiotic exposure prior to
diagnostic sampling was not measured in either cohort, which may have
contributed to culture negativity in the absence of other major demographic
differences. While data were collected prospectively, the retrospective
nature of this analysis and missing data mean that definitive conclusions
are unable to be drawn with regards to the sensitivity and utility of
current diagnostic criteria in the setting of CN PJI.</p>
      <p id="d1e2735">Despite improved outcomes, CN PJI continues to represent a significant
management challenge for surgeons and physicians alike. As such, clarity
with regards to optimal surgical management strategies is needed. While it
has been previously recommended that two-stage revisions be considered as the
optimal definitive surgical management strategy in all CN PJIs  (Ibrahim
et al., 2018), our findings instead emphasize the importance of precise
infection-type classifications in allowing for a more nuanced approached to
CN PJI diagnosis and management. This important interplay has been described
previously  (Davis et al., 2022) and highlights a crucial need to base
definitive surgical management decisions on PJI infection type using
standardized classification methods, regardless of culture status.</p>
      <p id="d1e2738">The use of a standardized yet comprehensive approach to PJI diagnostic
sampling is reliant upon the collaborative efforts of infectious diseases
physicians, pathologists, and orthopaedic surgeons, and it should be guided by
available evidence to optimize the sensitivity and specificity of PJI
detection. In high-volume centres, preprepared sterile sampling kits have
the potential to optimize sampling technique and uniformity  (Larsen et
al., 2014), while laboratory-based protocols addressing PJI specimen
processing and multidisciplinary case-based discussions should be
implemented to foster a culture of best practice and improve PJI outcomes.</p>
</sec>
<sec id="Ch1.S5" sec-type="conclusions">
  <label>5</label><title>Conclusions</title>
      <p id="d1e2750">In conclusion, CN PJIs are almost indistinguishable from a broader CP PJI
cohort while possessing an overall improved prognosis. When applied in a
real-life setting, current PJI diagnostic guidelines vary substantially
in their ability to detect CN PJI; this highlights the importance of
comprehensive diagnostic sampling, including non-culture-based methods, at
the time of any revision arthroplasty or DAIR procedure. Like CP PJI,
definitive surgical management strategies should be determined by careful
assessment of infection type, rather than by culture status alone.</p>
</sec>

      
      </body>
    <back><notes notes-type="dataavailability"><title>Data availability</title>

      <p id="d1e2757">The PIANO dataset is not yet publicly available, as preplanned analyses by the PIANO study group are ongoing. In the meantime, a de-identified  version of the dataset can be accessed by submitting a research proposal to the PIANO study management committee (who are the data custodians) for approval. Proposals can be addressed to Joshua Davis (joshua.davis@health.nsw.gov.au).</p>
  </notes><app-group>
        <supplementary-material position="anchor"><p id="d1e2760">The supplement related to this article is available online at: <inline-supplementary-material xlink:href="https://doi.org/10.5194/jbji-7-203-2022-supplement" xlink:title="pdf">https://doi.org/10.5194/jbji-7-203-2022-supplement</inline-supplementary-material>.</p></supplementary-material>
        </app-group><notes notes-type="authorcontribution"><title>Author contributions</title>

      <p id="d1e2769">LM, SM, DLP, JOR, BC, and JSD were responsible for conceptualization and
investigation. JSD provided supervision for SB with respect to the methodology, formal
analysis, and composition of the manuscript. LM, SM, DLP, JOR, BC, and
JSD assisted in the reviewing and editing of the manuscript.</p>
  </notes><notes notes-type="competinginterests"><title>Competing interests</title>

      <p id="d1e2775">The contact author has declared that none of the authors has any competing interests.</p>
  </notes><notes notes-type="specialsection"><title>Ethical statement</title>
    

      <p id="d1e2783">Ethical approvals were obtained from each participating site, and the PIANO
study was prospectively registered (ANZCTR12615001357549). All participants
provided written informed consent.</p>
  </notes><notes notes-type="disclaimer"><title>Disclaimer</title>

      <p id="d1e2789">Publisher's note: Copernicus Publications remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
  </notes><ack><title>Acknowledgements</title><p id="d1e2795">We wish to acknowledge the contributions of the PIANO investigators: Stephen
Graves, Eugene Athan, Chris Luey, Paul Huggan, Kate Grimwade, Kerry Read,
Piers Yates, Renjy Nelson, Marjoree Sehu, Adrienne Torda, Alistair Reid,
Craig Aboltins, Peter Leung, Thi Aung, Roy Chean, Darcie Cooper, Babak Rad,
Archana Sud, Kellie Schneider, Vana Nagendra, Stephen McBride, Mark
Loewenthal, David Looke, Christopher Lemoh, David Campbell, Lucian Bogdan
Solomon, Nora Mutalima, and Tony Allworth.</p></ack><notes notes-type="reviewstatement"><title>Review statement</title>

      <p id="d1e2800">This paper was edited by Parham Sendi and reviewed by three anonymous referees.</p>
  </notes><ref-list>
    <title>References</title>

      <ref id="bib1.bib1"><label>1</label><?label 1?><mixed-citation>
Alijanipour, P., Adeli, B., Hansen, E. N., Chen, A. F., and
Parvizi, J.: Intraoperative purulence is not reliable for diagnosing
periprosthetic joint infection,  J Arthroplasty, 30, 1403–1406,
2015.</mixed-citation></ref>
      <ref id="bib1.bib2"><label>2</label><?label 1?><mixed-citation>Berbari, E. F., Marculescu, C., Sia, I., Lahr, B. D., Hanssen, A. D.,
Steckelberg, J. M., Gullerud, R., and Osmon, D. R.: Culture-Negative
Prosthetic Joint Infection, Clin. Infect. Dis., 45, 1113–1119,
<ext-link xlink:href="https://doi.org/10.1086/522184" ext-link-type="DOI">10.1086/522184</ext-link>, 2007.</mixed-citation></ref>
      <ref id="bib1.bib3"><label>3</label><?label 1?><mixed-citation>Choi, H.-R., Kwon, Y.-M., Freiberg, A. A., Nelson, S. B., and Malchau, H.:
Periprosthetic joint infection with negative culture results: clinical
characteristics and treatment outcome,   J. Arthroplasty, 28,
899–903, 2013.</mixed-citation></ref>
      <ref id="bib1.bib4"><label>4</label><?label 1?><mixed-citation>Davis, J. S., Metcalf, S., Clark, B., Robinson, J. O., Huggan, P., Luey, C.,
McBride, S., Aboltins, C., Nelson, R., Campbell, D., Solomon, L. B.,
Schneider, K., Loewenthal, M. R., Yates, P., Athan, E., Cooper, D., Rad, B.,
Allworth, T., Reid, A., Read, K., Leung, P., Sud, A., Nagendra, V., Chean,
R., Lemoh, C., Mutalima, N., Tran, T., Grimwade, K., Sehu, M., Looke, D.,
Torda, A., Aung, T., Graves, S., Paterson, D. L., and Manning, L.:
Predictors of Treatment Success After Periprosthetic Joint Infection:
24-Month Follow up From a Multicenter Prospective Observational Cohort Study
of 653 Patients, Open Forum Infectious Diseases, 9, ofac048,
<ext-link xlink:href="https://doi.org/10.1093/ofid/ofac048" ext-link-type="DOI">10.1093/ofid/ofac048</ext-link>, 2022.</mixed-citation></ref>
      <ref id="bib1.bib5"><label>5</label><?label 1?><mixed-citation>Del Pozo, J. L. and Patel, R.: Infection Associated with Prosthetic Joints,
New Engl. J. Med., 361, 787–794, <ext-link xlink:href="https://doi.org/10.1056/NEJMcp0905029" ext-link-type="DOI">10.1056/NEJMcp0905029</ext-link>,
2009.</mixed-citation></ref>
      <ref id="bib1.bib6"><label>6</label><?label 1?><mixed-citation>Foster, A. L., Cutbush, K., Ezure, Y., Schuetz, M. A., Crawford, R., and
Paterson, D. L.: Cutibacterium acnes in shoulder surgery: a scoping review
of strategies for prevention, diagnosis, and treatment, J. Shoulder
Elb. Surg., 30, 1410–1422, <ext-link xlink:href="https://doi.org/10.1016/j.jse.2020.11.011" ext-link-type="DOI">10.1016/j.jse.2020.11.011</ext-link>, 2021.</mixed-citation></ref>
      <ref id="bib1.bib7"><label>7</label><?label 1?><mixed-citation>Ibrahim, M., Twaij, H., and Haddad, F.: Two-stage revision for the
culture-negative infected total hip arthroplasty: A comparative study,
Bone  Joint J., 100, 3–8, 2018.</mixed-citation></ref>
      <ref id="bib1.bib8"><label>8</label><?label 1?><mixed-citation>Kang, J.-S., Shin, E.-H., Roh, T.-H., Na, Y., Moon, K. H., and Park, J.-H.:
Long-term clinical outcome of two-stage revision surgery for infected hip
arthroplasty using cement spacer: Culture negative versus culture positive,
J. Orthop. Surg.-Hong K., 26,
2309499017754095, <ext-link xlink:href="https://doi.org/10.1177/2309499017754095" ext-link-type="DOI">10.1177/2309499017754095</ext-link>, 2018.</mixed-citation></ref>
      <ref id="bib1.bib9"><label>9</label><?label 1?><mixed-citation>Khalfaoui, M. Y. and Yassa, R.: Crystal arthropathy following knee
arthroplasty: A review of the literature, Int. J.
Orthop., 2, 411–417, 2015.</mixed-citation></ref>
      <ref id="bib1.bib10"><label>10</label><?label 1?><mixed-citation>Kim, Y.-H., Kulkarni, S. S., Park, J.-W., Kim, J.-S., Oh, H.-K., and
Rastogi, D.: Comparison of infection control rates and clinical outcomes in
culture-positive and culture-negative infected total-knee arthroplasty,
J. Orthop., 12, S37–S43, <ext-link xlink:href="https://doi.org/10.1016/j.jor.2015.01.020" ext-link-type="DOI">10.1016/j.jor.2015.01.020</ext-link>, 2015.</mixed-citation></ref>
      <ref id="bib1.bib11"><label>11</label><?label 1?><mixed-citation>Larsen, L. H., Xu, Y., Simonsen, O., Pedersen, C., Schønheyder, H. C.,
Thomsen, T. R., and Group, P. S.: “All in a box” a concept for optimizing
microbiological diagnostic sampling in prosthetic joint infections, BMC
Research Notes, 7, p. 418, <ext-link xlink:href="https://doi.org/10.1186/1756-0500-7-418" ext-link-type="DOI">10.1186/1756-0500-7-418</ext-link>, 2014.</mixed-citation></ref>
      <ref id="bib1.bib12"><label>12</label><?label 1?><mixed-citation>Malekzadeh, D., Osmon, D. R., Lahr, B. D., Hanssen, A. D., and Berbari, E.
F.: Prior Use of Antimicrobial Therapy is a Risk Factor for Culture-negative
Prosthetic Joint Infection, Clin. Orthop. Relat. R., 468,
2039–2045, <ext-link xlink:href="https://doi.org/10.1007/s11999-010-1338-0" ext-link-type="DOI">10.1007/s11999-010-1338-0</ext-link>, 2010.</mixed-citation></ref>
      <ref id="bib1.bib13"><label>13</label><?label 1?><mixed-citation>Manning, L., Metcalf, S., Clark, B., Robinson, J. O., Huggan, P., Luey, C.,
McBride, S., Aboltins, C., Nelson, R., Campbell, D., Solomon, L. B.,
Schneider, K., Loewenthal, M., Yates, P., Athan, E., Cooper, D., Rad, B.,
Allworth, T., Reid, A., Read, K., Leung, P., Sud, A., Nagendra, V., Chean,
R., Lemoh, C., Mutalima, N., Grimwade, K., Sehu, M., Torda, A., Aung, T.,
Graves, S., Paterson, D., and Davis, J.: Clinical Characteristics, Etiology,
and Initial Management Strategy of Newly Diagnosed Periprosthetic Joint
Infection: A Multicenter, Prospective Observational Cohort Study of 783
Patients, Open Forum Infectious Diseases, 7, ofaa068,
<ext-link xlink:href="https://doi.org/10.1093/OFID/OFAA068" ext-link-type="DOI">10.1093/OFID/OFAA068</ext-link>, 2020.</mixed-citation></ref>
      <ref id="bib1.bib14"><label>14</label><?label 1?><mixed-citation>McNally, M., Sousa, R., Wouthuyzen-Bakker, M., Chen, A. F., Soriano, A.,
Vogely, H. C., Clauss, M., Higuera, C. A., and Trebše, R.: The EBJIS
definition of periprosthetic joint infection, Bone Joint. J., 103-b, 18–25,
<ext-link xlink:href="https://doi.org/10.1302/0301-620x.103b1.Bjj-2020-1381.R1" ext-link-type="DOI">10.1302/0301-620x.103b1.Bjj-2020-1381.R1</ext-link>, 2021.</mixed-citation></ref>
      <ref id="bib1.bib15"><label>15</label><?label 1?><mixed-citation>Moore, A. J., Blom, A. W., Whitehouse, M. R., and Gooberman-Hill, R.: Deep
prosthetic joint infection: a qualitative study of the impact on patients
and their experiences of revision surgery, BMJ Open, 5, e009495,
<ext-link xlink:href="https://doi.org/10.1136/bmjopen-2015-009495" ext-link-type="DOI">10.1136/bmjopen-2015-009495</ext-link>, 2015.</mixed-citation></ref>
      <ref id="bib1.bib16"><label>16</label><?label 1?><mixed-citation>Osmon, D. R., Berbari, E. F., Berendt, A. R., Lew, D., Zimmerli, W.,
Steckelberg, J. M., Rao, N., Hanssen, A., and Wilson, W. R.: Diagnosis and
Management of Prosthetic Joint Infection: Clinical Practice Guidelines by
the Infectious Diseases Society of America, Clin. Infect. Dis.,
56, 1–10, <ext-link xlink:href="https://doi.org/10.1093/cid/cis803" ext-link-type="DOI">10.1093/cid/cis803</ext-link>, 2013.</mixed-citation></ref>
      <ref id="bib1.bib17"><label>17</label><?label 1?><mixed-citation>Parikh, M. S. and Antony, S.: A comprehensive review of the diagnosis and
management of prosthetic joint infections in the absence of positive
cultures, J. Infect. Public Heal., 9, 545–556,
<ext-link xlink:href="https://doi.org/10.1016/j.jiph.2015.12.001" ext-link-type="DOI">10.1016/j.jiph.2015.12.001</ext-link>, 2015.</mixed-citation></ref>
      <ref id="bib1.bib18"><label>18</label><?label 1?><mixed-citation>Parvizi, J., Gehrke, T., and Chen, A.: Proceedings of the international
consensus on periprosthetic joint infection,   Bone Joint J.,
95, 1450–1452, 2013.</mixed-citation></ref>
      <ref id="bib1.bib19"><label>19</label><?label 1?><mixed-citation>Parvizi, J., Tan, T. L., Goswami, K., Higuera, C., Della Valle, C., Chen, A.
F., and Shohat, N.: The 2018 Definition of Periprosthetic Hip and Knee
Infection: An Evidence-Based and Validated Criteria,  J.
Arthroplasty, 33, 1309-1314.e1302, <ext-link xlink:href="https://doi.org/10.1016/j.arth.2018.02.078" ext-link-type="DOI">10.1016/j.arth.2018.02.078</ext-link>, 2018.</mixed-citation></ref>
      <ref id="bib1.bib20"><label>20</label><?label 1?><mixed-citation>Paz, Z., Zhu, C., Lieber, S. B., Fowler, M. L., and Shmerling, R. H.:
Presentation and Outcomes of Peri-Prosthetic Joint Infection: A Comparison
of Culture-Positive and Culture-Negative Disease, Surg. Infect., 22,
828–835, <ext-link xlink:href="https://doi.org/10.1089/sur.2020.302" ext-link-type="DOI">10.1089/sur.2020.302</ext-link>, 2021.</mixed-citation></ref>
      <ref id="bib1.bib21"><label>21</label><?label 1?><mixed-citation>Peel, T. N., Dowsey, M. M., Aboltins, C. A., Daffy, J. R., Stanley, P. A.,
Buising, K. L., and Choong, P. F.: Culture negative prosthetic joint
infection – a description of current treatment and outcomes, Clin.
Microbiol., 2, 1–5, 2013.</mixed-citation></ref>
      <ref id="bib1.bib22"><label>22</label><?label 1?><mixed-citation>Peel, T. N., Spelman, T., Dylla, B. L., Hughes, J. G., Greenwood-Quaintance,
K. E., Cheng, A. C., Mandrekar, J. N., and Patel, R.: Optimal periprosthetic
tissue specimen number for diagnosis of prosthetic joint infection, J.
Clin. Microbiol., 55, 234–243, 2017.</mixed-citation></ref>
      <ref id="bib1.bib23"><label>23</label><?label 1?><mixed-citation>Quinlan, N. D., Werner, B. C., Brown, T. E., and Browne, J. A.: Risk of
Prosthetic Joint Infection Increases Following Early Aseptic Revision
Surgery of Total Hip and Knee Arthroplasty,  J. Arthroplasty, 35,
3661–3667, <ext-link xlink:href="https://doi.org/10.1016/j.arth.2020.06.089" ext-link-type="DOI">10.1016/j.arth.2020.06.089</ext-link>, 2020.</mixed-citation></ref>
      <ref id="bib1.bib24"><label>24</label><?label 1?><mixed-citation>Reisener, M. and Perka, C.: Do Culture-Negative Periprosthetic Joint
Infections Have a Worse Outcome Than Culture-Positive Periprosthetic Joint
Infections? A Systematic Review and Meta-Analysis, BioMed Res.
Int., 2018, 6278012, <ext-link xlink:href="https://doi.org/10.1155/2018/6278012" ext-link-type="DOI">10.1155/2018/6278012</ext-link>, 2018.
</mixed-citation></ref><?xmltex \hack{\newpage}?>
      <ref id="bib1.bib25"><label>25</label><?label 1?><mixed-citation>Tsukayama, D. T., Estrada, R., and Gustilo, R. B.: Infection after Total Hip
Arthroplasty. A Study of the Treatment of One Hundred and Six Infections,
J.  Bone Joint Surg. Am., 78, 512–523,
<ext-link xlink:href="https://doi.org/10.2106/00004623-199604000-00005" ext-link-type="DOI">10.2106/00004623-199604000-00005</ext-link>, 1996.</mixed-citation></ref>
      <ref id="bib1.bib26"><label>26</label><?label 1?><mixed-citation>Zimmerli, W.: Clinical presentation and treatment of orthopaedic
implant-associated infection, J. Intern. Med., 276, 111–119,
<ext-link xlink:href="https://doi.org/10.1111/joim.12233" ext-link-type="DOI">10.1111/joim.12233</ext-link>, 2014.</mixed-citation></ref>

  </ref-list></back>
    <!--<article-title-html>Characteristics and outcomes of culture-negative prosthetic joint infections from the Prosthetic Joint Infection in Australia and New Zealand  Observational (PIANO) cohort study</article-title-html>
<abstract-html/>
<ref-html id="bib1.bib1"><label>1</label><mixed-citation>
Alijanipour, P., Adeli, B., Hansen, E. N., Chen, A. F., and
Parvizi, J.: Intraoperative purulence is not reliable for diagnosing
periprosthetic joint infection,  J Arthroplasty, 30, 1403–1406,
2015.
</mixed-citation></ref-html>
<ref-html id="bib1.bib2"><label>2</label><mixed-citation>Berbari, E. F., Marculescu, C., Sia, I., Lahr, B. D., Hanssen, A. D.,
Steckelberg, J. M., Gullerud, R., and Osmon, D. R.: Culture-Negative
Prosthetic Joint Infection, Clin. Infect. Dis., 45, 1113–1119,
<a href="https://doi.org/10.1086/522184" target="_blank">https://doi.org/10.1086/522184</a>, 2007.
</mixed-citation></ref-html>
<ref-html id="bib1.bib3"><label>3</label><mixed-citation>Choi, H.-R., Kwon, Y.-M., Freiberg, A. A., Nelson, S. B., and Malchau, H.:
Periprosthetic joint infection with negative culture results: clinical
characteristics and treatment outcome,   J. Arthroplasty, 28,
899–903, 2013.
</mixed-citation></ref-html>
<ref-html id="bib1.bib4"><label>4</label><mixed-citation>Davis, J. S., Metcalf, S., Clark, B., Robinson, J. O., Huggan, P., Luey, C.,
McBride, S., Aboltins, C., Nelson, R., Campbell, D., Solomon, L. B.,
Schneider, K., Loewenthal, M. R., Yates, P., Athan, E., Cooper, D., Rad, B.,
Allworth, T., Reid, A., Read, K., Leung, P., Sud, A., Nagendra, V., Chean,
R., Lemoh, C., Mutalima, N., Tran, T., Grimwade, K., Sehu, M., Looke, D.,
Torda, A., Aung, T., Graves, S., Paterson, D. L., and Manning, L.:
Predictors of Treatment Success After Periprosthetic Joint Infection:
24-Month Follow up From a Multicenter Prospective Observational Cohort Study
of 653 Patients, Open Forum Infectious Diseases, 9, ofac048,
<a href="https://doi.org/10.1093/ofid/ofac048" target="_blank">https://doi.org/10.1093/ofid/ofac048</a>, 2022.
</mixed-citation></ref-html>
<ref-html id="bib1.bib5"><label>5</label><mixed-citation>Del Pozo, J. L. and Patel, R.: Infection Associated with Prosthetic Joints,
New Engl. J. Med., 361, 787–794, <a href="https://doi.org/10.1056/NEJMcp0905029" target="_blank">https://doi.org/10.1056/NEJMcp0905029</a>,
2009.
</mixed-citation></ref-html>
<ref-html id="bib1.bib6"><label>6</label><mixed-citation>Foster, A. L., Cutbush, K., Ezure, Y., Schuetz, M. A., Crawford, R., and
Paterson, D. L.: Cutibacterium acnes in shoulder surgery: a scoping review
of strategies for prevention, diagnosis, and treatment, J. Shoulder
Elb. Surg., 30, 1410–1422, <a href="https://doi.org/10.1016/j.jse.2020.11.011" target="_blank">https://doi.org/10.1016/j.jse.2020.11.011</a>, 2021.
</mixed-citation></ref-html>
<ref-html id="bib1.bib7"><label>7</label><mixed-citation>Ibrahim, M., Twaij, H., and Haddad, F.: Two-stage revision for the
culture-negative infected total hip arthroplasty: A comparative study,
Bone  Joint J., 100, 3–8, 2018.
</mixed-citation></ref-html>
<ref-html id="bib1.bib8"><label>8</label><mixed-citation>Kang, J.-S., Shin, E.-H., Roh, T.-H., Na, Y., Moon, K. H., and Park, J.-H.:
Long-term clinical outcome of two-stage revision surgery for infected hip
arthroplasty using cement spacer: Culture negative versus culture positive,
J. Orthop. Surg.-Hong K., 26,
2309499017754095, <a href="https://doi.org/10.1177/2309499017754095" target="_blank">https://doi.org/10.1177/2309499017754095</a>, 2018.
</mixed-citation></ref-html>
<ref-html id="bib1.bib9"><label>9</label><mixed-citation>Khalfaoui, M. Y. and Yassa, R.: Crystal arthropathy following knee
arthroplasty: A review of the literature, Int. J.
Orthop., 2, 411–417, 2015.
</mixed-citation></ref-html>
<ref-html id="bib1.bib10"><label>10</label><mixed-citation>Kim, Y.-H., Kulkarni, S. S., Park, J.-W., Kim, J.-S., Oh, H.-K., and
Rastogi, D.: Comparison of infection control rates and clinical outcomes in
culture-positive and culture-negative infected total-knee arthroplasty,
J. Orthop., 12, S37–S43, <a href="https://doi.org/10.1016/j.jor.2015.01.020" target="_blank">https://doi.org/10.1016/j.jor.2015.01.020</a>, 2015.
</mixed-citation></ref-html>
<ref-html id="bib1.bib11"><label>11</label><mixed-citation>Larsen, L. H., Xu, Y., Simonsen, O., Pedersen, C., Schønheyder, H. C.,
Thomsen, T. R., and Group, P. S.: “All in a box” a concept for optimizing
microbiological diagnostic sampling in prosthetic joint infections, BMC
Research Notes, 7, p. 418, <a href="https://doi.org/10.1186/1756-0500-7-418" target="_blank">https://doi.org/10.1186/1756-0500-7-418</a>, 2014.
</mixed-citation></ref-html>
<ref-html id="bib1.bib12"><label>12</label><mixed-citation>Malekzadeh, D., Osmon, D. R., Lahr, B. D., Hanssen, A. D., and Berbari, E.
F.: Prior Use of Antimicrobial Therapy is a Risk Factor for Culture-negative
Prosthetic Joint Infection, Clin. Orthop. Relat. R., 468,
2039–2045, <a href="https://doi.org/10.1007/s11999-010-1338-0" target="_blank">https://doi.org/10.1007/s11999-010-1338-0</a>, 2010.
</mixed-citation></ref-html>
<ref-html id="bib1.bib13"><label>13</label><mixed-citation>Manning, L., Metcalf, S., Clark, B., Robinson, J. O., Huggan, P., Luey, C.,
McBride, S., Aboltins, C., Nelson, R., Campbell, D., Solomon, L. B.,
Schneider, K., Loewenthal, M., Yates, P., Athan, E., Cooper, D., Rad, B.,
Allworth, T., Reid, A., Read, K., Leung, P., Sud, A., Nagendra, V., Chean,
R., Lemoh, C., Mutalima, N., Grimwade, K., Sehu, M., Torda, A., Aung, T.,
Graves, S., Paterson, D., and Davis, J.: Clinical Characteristics, Etiology,
and Initial Management Strategy of Newly Diagnosed Periprosthetic Joint
Infection: A Multicenter, Prospective Observational Cohort Study of 783
Patients, Open Forum Infectious Diseases, 7, ofaa068,
<a href="https://doi.org/10.1093/OFID/OFAA068" target="_blank">https://doi.org/10.1093/OFID/OFAA068</a>, 2020.
</mixed-citation></ref-html>
<ref-html id="bib1.bib14"><label>14</label><mixed-citation>McNally, M., Sousa, R., Wouthuyzen-Bakker, M., Chen, A. F., Soriano, A.,
Vogely, H. C., Clauss, M., Higuera, C. A., and Trebše, R.: The EBJIS
definition of periprosthetic joint infection, Bone Joint. J., 103-b, 18–25,
<a href="https://doi.org/10.1302/0301-620x.103b1.Bjj-2020-1381.R1" target="_blank">https://doi.org/10.1302/0301-620x.103b1.Bjj-2020-1381.R1</a>, 2021.
</mixed-citation></ref-html>
<ref-html id="bib1.bib15"><label>15</label><mixed-citation>Moore, A. J., Blom, A. W., Whitehouse, M. R., and Gooberman-Hill, R.: Deep
prosthetic joint infection: a qualitative study of the impact on patients
and their experiences of revision surgery, BMJ Open, 5, e009495,
<a href="https://doi.org/10.1136/bmjopen-2015-009495" target="_blank">https://doi.org/10.1136/bmjopen-2015-009495</a>, 2015.
</mixed-citation></ref-html>
<ref-html id="bib1.bib16"><label>16</label><mixed-citation>Osmon, D. R., Berbari, E. F., Berendt, A. R., Lew, D., Zimmerli, W.,
Steckelberg, J. M., Rao, N., Hanssen, A., and Wilson, W. R.: Diagnosis and
Management of Prosthetic Joint Infection: Clinical Practice Guidelines by
the Infectious Diseases Society of America, Clin. Infect. Dis.,
56, 1–10, <a href="https://doi.org/10.1093/cid/cis803" target="_blank">https://doi.org/10.1093/cid/cis803</a>, 2013.
</mixed-citation></ref-html>
<ref-html id="bib1.bib17"><label>17</label><mixed-citation>Parikh, M. S. and Antony, S.: A comprehensive review of the diagnosis and
management of prosthetic joint infections in the absence of positive
cultures, J. Infect. Public Heal., 9, 545–556,
<a href="https://doi.org/10.1016/j.jiph.2015.12.001" target="_blank">https://doi.org/10.1016/j.jiph.2015.12.001</a>, 2015.
</mixed-citation></ref-html>
<ref-html id="bib1.bib18"><label>18</label><mixed-citation>Parvizi, J., Gehrke, T., and Chen, A.: Proceedings of the international
consensus on periprosthetic joint infection,   Bone Joint J.,
95, 1450–1452, 2013.
</mixed-citation></ref-html>
<ref-html id="bib1.bib19"><label>19</label><mixed-citation>Parvizi, J., Tan, T. L., Goswami, K., Higuera, C., Della Valle, C., Chen, A.
F., and Shohat, N.: The 2018 Definition of Periprosthetic Hip and Knee
Infection: An Evidence-Based and Validated Criteria,  J.
Arthroplasty, 33, 1309-1314.e1302, <a href="https://doi.org/10.1016/j.arth.2018.02.078" target="_blank">https://doi.org/10.1016/j.arth.2018.02.078</a>, 2018.
</mixed-citation></ref-html>
<ref-html id="bib1.bib20"><label>20</label><mixed-citation>Paz, Z., Zhu, C., Lieber, S. B., Fowler, M. L., and Shmerling, R. H.:
Presentation and Outcomes of Peri-Prosthetic Joint Infection: A Comparison
of Culture-Positive and Culture-Negative Disease, Surg. Infect., 22,
828–835, <a href="https://doi.org/10.1089/sur.2020.302" target="_blank">https://doi.org/10.1089/sur.2020.302</a>, 2021.
</mixed-citation></ref-html>
<ref-html id="bib1.bib21"><label>21</label><mixed-citation>Peel, T. N., Dowsey, M. M., Aboltins, C. A., Daffy, J. R., Stanley, P. A.,
Buising, K. L., and Choong, P. F.: Culture negative prosthetic joint
infection – a description of current treatment and outcomes, Clin.
Microbiol., 2, 1–5, 2013.
</mixed-citation></ref-html>
<ref-html id="bib1.bib22"><label>22</label><mixed-citation>Peel, T. N., Spelman, T., Dylla, B. L., Hughes, J. G., Greenwood-Quaintance,
K. E., Cheng, A. C., Mandrekar, J. N., and Patel, R.: Optimal periprosthetic
tissue specimen number for diagnosis of prosthetic joint infection, J.
Clin. Microbiol., 55, 234–243, 2017.
</mixed-citation></ref-html>
<ref-html id="bib1.bib23"><label>23</label><mixed-citation>Quinlan, N. D., Werner, B. C., Brown, T. E., and Browne, J. A.: Risk of
Prosthetic Joint Infection Increases Following Early Aseptic Revision
Surgery of Total Hip and Knee Arthroplasty,  J. Arthroplasty, 35,
3661–3667, <a href="https://doi.org/10.1016/j.arth.2020.06.089" target="_blank">https://doi.org/10.1016/j.arth.2020.06.089</a>, 2020.
</mixed-citation></ref-html>
<ref-html id="bib1.bib24"><label>24</label><mixed-citation>Reisener, M. and Perka, C.: Do Culture-Negative Periprosthetic Joint
Infections Have a Worse Outcome Than Culture-Positive Periprosthetic Joint
Infections? A Systematic Review and Meta-Analysis, BioMed Res.
Int., 2018, 6278012, <a href="https://doi.org/10.1155/2018/6278012" target="_blank">https://doi.org/10.1155/2018/6278012</a>, 2018.

</mixed-citation></ref-html>
<ref-html id="bib1.bib25"><label>25</label><mixed-citation>Tsukayama, D. T., Estrada, R., and Gustilo, R. B.: Infection after Total Hip
Arthroplasty. A Study of the Treatment of One Hundred and Six Infections,
J.  Bone Joint Surg. Am., 78, 512–523,
<a href="https://doi.org/10.2106/00004623-199604000-00005" target="_blank">https://doi.org/10.2106/00004623-199604000-00005</a>, 1996.
</mixed-citation></ref-html>
<ref-html id="bib1.bib26"><label>26</label><mixed-citation>Zimmerli, W.: Clinical presentation and treatment of orthopaedic
implant-associated infection, J. Intern. Med., 276, 111–119,
<a href="https://doi.org/10.1111/joim.12233" target="_blank">https://doi.org/10.1111/joim.12233</a>, 2014.
</mixed-citation></ref-html>--></article>
